Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300546 · ClinicalTrials.gov registry record · Phase 4
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
A Phase 4 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT01300546 is a Phase 4 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 40 participants.
The verdict
NCT01300546, a Phase 4 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the hypothesis that use of pharmacological and non-pharmacological interventions may allow subjects at high risk for chronic migraine to avoid or reverse the transformation of episodic migraine to chronic migraine.
Interventions
- DRUG Naproxen Sodium
- DRUG Sumatriptan/Naproxen Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01300546
The ClinicalTrials.gov registry entry for NCT01300546 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cady, Roger, M.D., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naproxen Sodium is the first listed.
NCT01300546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01300546 about?
NCT01300546 is a clinical study titled "Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine". This study is being conducted to evaluate the hypothesis that use of pharmacological and non-pharmacological interventions may allow subjects at high risk for chronic migraine to avoid or reverse the transformation of episodic migraine to chronic migraine.
What is the current status of trial NCT01300546?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2010-12. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01300546?
The interventions under investigation include: Naproxen Sodium (DRUG), Sumatriptan/Naproxen Sodium (DRUG).
Who is sponsoring clinical trial NCT01300546?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.